Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer.
Forsythe N, Refaat A, Javadi A, Khawaja H, Weir JA, Emam H, Allen WL, Burkamp F, Popovici V, Jithesh PV, Isella C, Labonte MJ, Mills IG, Johnston PG, Van Schaeybroeck S. Forsythe N, et al. Among authors: labonte mj. Mol Cancer Ther. 2018 Jun;17(6):1280-1290. doi: 10.1158/1535-7163.MCT-17-0603. Epub 2018 Feb 26. Mol Cancer Ther. 2018. PMID: 29483217 Free PMC article.
A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.
LaBonte MJ, Yang D, Zhang W, Wilson PM, Nagarwala YM, Koch KM, Briner C, Kaneko T, Rha SY, Gladkov O, Urba SG, Sakaeva D, Pishvaian MJ, Hsieh RK, Lee WP, Lenz HJ. LaBonte MJ, et al. Mol Cancer Ther. 2016 Sep;15(9):2251-8. doi: 10.1158/1535-7163.MCT-15-0908. Epub 2016 Jun 20. Mol Cancer Ther. 2016. PMID: 27325685 Free PMC article. Clinical Trial.
Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma.
Armstrong CWD, Coulter JA, Ong CW, Maxwell PJ, Walker S, Butterworth KT, Lyubomska O, Berlingeri S, Gallagher R, O'Sullivan JM, Jain S, Mills IG, Prise KM, Bristow RG, LaBonte MJ, Waugh DJJ. Armstrong CWD, et al. Among authors: labonte mj. NAR Cancer. 2020 Sep;2(3):zcaa012. doi: 10.1093/narcan/zcaa012. Epub 2020 Jul 3. NAR Cancer. 2020. PMID: 32743555 Free PMC article.
Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers.
Maxwell PJ, McKechnie M, Armstrong CW, Manley JM, Ong CW, Worthington J, Mills IG, Longley DB, Quigley JP, Zoubeidi A, de Bono JS, Deryugina E, LaBonte MJ, Waugh DJJ. Maxwell PJ, et al. Among authors: labonte mj. Mol Cancer Res. 2022 Jun 3;20(6):841-853. doi: 10.1158/1541-7786.MCR-21-0780. Mol Cancer Res. 2022. PMID: 35302608 Free PMC article.
Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer.
Khawaja H, Briggs R, Latimer CH, Rassel M, Griffin D, Hanson L, Bardelli A, Di Nicolantonio F, McDade SS, Scott CJ, Lambe S, Maurya M, Lindner AU, Prehn JHM, Sousa J, Winnington C, LaBonte MJ, Ross S, Van Schaeybroeck S. Khawaja H, et al. Among authors: labonte mj. Mol Cancer Ther. 2023 Jan 3;22(1):135-149. doi: 10.1158/1535-7163.MCT-22-0301. Mol Cancer Ther. 2023. PMID: 36279564 Free PMC article.
Predictive molecular classifiers in colorectal cancer.
Bohanes P, LaBonte MJ, Winder T, Lenz HJ. Bohanes P, et al. Among authors: labonte mj. Semin Oncol. 2011 Aug;38(4):576-87. doi: 10.1053/j.seminoncol.2011.05.012. Semin Oncol. 2011. PMID: 21810517 Review.
56 results